loader

World Tenders & Procurement Opportunities

551233- Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a, Paragraph 8 of the German Social Code (SGB V) through an open-house model for the active ingredient certolizumab pegol (WHO ATC code: L04AB05)

World Biggest Tenders Source

This tender with title 551233- Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a, Paragraph 8 of the German Social Code (SGB V) through an open-house model for the active ingredient certolizumab pegol (WHO ATC code: L04AB05) has been published on Bidding Source portal dated 28 Aug 2025 for the country of Germany. It has been categorized on Pharmaceutical products. For similar tenders you can see tenders mentioned below of this page.

General Information

551233- Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a, Paragraph 8 of the German Social Code (SGB V) through an open-house model for the active ingredient certolizumab pegol (WHO ATC code: L04AB05)
Invitation for Bids
551233
Germany
28 Aug 2025
31 Oct 2026
English
Pharmaceutical products

For viewing full details of tenders, you should Log in to your account. If not registered yet, Please Register Now

Or Request a call back now and one of our representatives will contact you. Contact us

Similar Tenders

551011- Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a, Paragraph 8 of the Social Code Book V (SGB V) through an open-house model for the active ingredient brinzolamide/brimonidine (official ATC code: S01EC24) Germany 555276- Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-11 - Eltrombopag Germany 551515- Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a, Paragraph 8 of the Social Code Book V (SGB V) through an open-house model for the active ingredient pomalidomide (ATC code according to WHO: L04AX06) Germany 554576-Awarded - Germany – Pharmaceutical products – Pharmaceutical contracts with accession option Germany 555917- Germany – Pharmaceutical products – Medicines containing the active ingredient rivaroxaban (ATC: B01AF01 - in all strengths except 2.5 mg per divided oral dosage form) Germany 552695- Germany – Pharmaceutical products – Medicines containing the active ingredient Eltrombopag (ATC: B02BX05) Germany 556029- Germany – Pharmaceutical products – Pharmaceutical contracts with accession option Germany 552774- Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a, Paragraph 8 of the German Social Code (SGB V) through an open-house model for the active ingredient omalizumab (ATC code according to WHO: R03DX05) Germany 552727-Awarded - Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 SGB V between IKK classic and LFB Biomedicaments for Willfact and Cevenfacta Germany 550903- Germany – Pharmaceutical products – Open house drug discount agreements for the active ingredient Rivaroxaban, only film-coated tablets excl. strength 2.5 mg, ATC B01AF01 Germany
No. 12, 1 st floor, Block B2, EGS Business Park, World Trade Center, Bakirkoy - Istanbul - Turkey
info@biddingsource.com
24 X 7 online support
TOP
For viewing latest tenders published for your business in all over the World: Sign in Join free
For accessing full details of Tenders, Kindly choose the Plan that works for you: View Subscription Plans